P354: Refinement and confirmation of psychometric properties of the Inflammatory Bowel Disease Distress Scale (IBD-DS): A new tool to measure disease-specific distressECCO '18 Vienna
2018
P355: Prevalence, clinical characteristics and outcomes of CMV colitis in a cohort of 95 patients with ulcerative colitis: A 7-year retrospective analysisECCO '18 Vienna
2018
P356: The role of endoscopic activity in the coagulation profile of clinical remission Crohn’s diseaseECCO '18 Vienna
2018
P357: Healthcare and medication utilisation in Singapore adult inflammatory bowel disease patients receiving immunomodulators and biologicsECCO '18 Vienna
2018
P358: Factors associated with disability in inflammatory bowel disease (IBD): A cross-sectional study in outpatientsECCO '18 Vienna
2018
P360: TrueColours ulcerative colitis (TCUC): Will patients with UC complete digital questionnaires in real-time?ECCO '18 Vienna
2018
P361: Patterns of use and durability of initial and sequential biological agents in a large Paediatric inflammatory bowel disease observational cohortECCO '18 Vienna
2018
P362: Six-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patientsECCO '18 Vienna
2018
P363: Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomesECCO '18 Vienna
2018
P364: Stopping azathioprine in monotherapy after very prolonged remission in inflammatory bowel disease patients: Novel relapse risk factorsECCO '18 Vienna
2018
P365: Biological interventions for induction and maintenance of mucosal healing in Crohn’s disease: A Cochrane systematic reviewECCO '18 Vienna
2018
P366: Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI)ECCO '18 Vienna
2018
P367: Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysisECCO '18 Vienna
2018
P368: Persistence of biologic therapy and mapping of sequential biologic use: Results of a single centre cohort with 841 patients treated over 18 yearsECCO '18 Vienna
2018
P369: Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with ulcerative colitis: A multicentre studyECCO '18 Vienna
2018
P370: Endosponge-assisted early surgical closure of ileal pouch-anal anastomotic leakage improves long-term outcomesECCO '18 Vienna
2018
P371: Vedolizumab is associated with changes in innate rather than T-cell immunity in patients with inflammatory bowel diseaseECCO '18 Vienna
2018